Cramer Passes on Exelon, Prefers AMD, ChannelAdvisor, This Stock Instead
Jim Cramer made the following calls on August 12th, 2013. What do you think about his picks?
Exelon Corp. (NYSE:EXC): Jim Cramer ranked this stock a Sell. Cramer previously ranked this stock a Sell on February 19, 2013. The stock’s 52-week high is $38.49, and its 52-week low is $28.40.
Exelon was not so lucky during the lightning round last night, as Cramer told viewers that, “I’ve got so many good ones … EXC is poorly run. I don’t want to touch it.” One Exelon’s companies, ComEd, is undergoing a $350 million bond sale in order to raise cash to pay down other debts and corporate expenses.
Advanced Micro Devices, Inc. (NYSE:AMD): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on July 24, 2013. The stock’s 52-week high is $4.65, and its 52-week low is $1.81.
Cramer reiterated his buy on AMD last night, telling viewers during the lightning round that, “I still like it. I think the gaming business is going to fill that company out.” The company has recently denied rumors of production delays on one of its upcoming new Kaveri advanced processing units.
ChannelAdvisor (NYSE:ECOM): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on July 30, 2013. The stock’s 52-week high is $25.39, and its 52-week low is $14.25.ChannelAdvisor has been on fire since its IPO this summer, and Cramer is still shouting for viewers to buy the stock, and CEO Scott Wingo, sat down with the Mad Money host last night to discuss the state of his business. Wingo cited the ever increasing proportion of retail sales purchased over the internet as room for growth, as his company looks to get products in front of consumers through creative advertising. He pointed to the company’s affinity for getting Chinese products in front of American consumers as an example of what ChannelAdvisor has been able to achieve.
Covance Inc. (NYSE:CVD): Jim Cramer ranked this stock a Buy. The stock’s 52-week high is $84.75, and its 52-week low is $46.15.
“Best in show. It is one of these ancillary drug and healthcare plays that keep going higher.” So said Cramer last night during the lightning round, bullish on a stock that just rolled out a new program to control costs and utilize their biopharmaceutical and medical device clients support to manage contracts in certain markets.
Don’t Miss: Needham: Apple Worth Less Than $600.